Bar Of Patent Suit Deductions Favors Drug Brands, Mylan Says
By David Hansen · July 3, 2019, 4:16 PM EDT
Barring Mylan from deducting $50 million in legal costs from patent infringement litigation would tilt the tax code in favor of brand-name drugmakers to the detriment of Mylan and other generic manufacturers,...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login